Dr. Elan's documentation, when it arrived through the relay system Lira had established for him, was exactly the kind of evidence she had suspected it would be and also more specific than she had dared hope. He was a careful man and a precise one, and he had spent three months constructing the record she had asked for with the thoroughness of someone who understood that what he was building needed to be unassailable.
The documentation established: the specific compounds present in Prince Edric's prescription medications over the past eighteen months, cross-referenced against the therapeutic protocols that the official treatment plan specified. The divergence was systematic rather than incidental — not the kind of drift that happened through pharmaceutical imprecision but the kind that happened when someone was making deliberate adjustments at a level of access that only one of the attending physicians had. The primary physician, a man named Cassel who had been in his position for two years — appointed after the previous primary physician's convenient retirement — had the specific access and the specific authority over the prescription formulation that made him the only possible source of the divergence.
The compound itself, when Elan had finally isolated and identified it, was the same black orchid derivative that the official trial record named as the banquet poison. Not a coincidence — a continuation.
Lira read the documentation at the safe house kitchen table and sat with what it meant. The banquet had not been a one-time event. The banquet had been the beginning of a long operation that was still running, nine years later, in the eastern wing of Castle Aldenmoor. The prince had survived the initial dose because he had survived; Draven had responded by adjusting to a longer timeline. Patient. Meticulous. Comfortable with waiting.
She wrote, in the Archive, the section she titled Current Administration, and she dated it with the precision of a document that needed to demonstrate its contemporaneity. It was the most recent piece of evidence in the Archive — more recent than anything else — and it transformed the Archive from a record of historical crimes into evidence of an ongoing one.
The treatment intervention required working with Elan across three weeks. The goal was not a cure — the accumulated damage of nine years of microdosing could not be undone quickly, and attempting rapid treatment would create symptoms of its own that would alert the primary physician. The goal was the cessation of the ongoing administration and the beginning of a genuinely therapeutic protocol that would, over months, allow whatever recovery was possible.
The mechanism: Elan had the authority to request secondary consultation on specific aspects of the prince's treatment — a normal medical process, one that Cassel would expect and could not refuse without triggering questions about his own management of the case. The secondary consultation gave Elan access to the specific medications in question. The replacements were prepared by Lira using the pharmaceutical knowledge she had built over a decade of careful study, compounds that matched the therapeutic description of what was being prescribed while omitting the component that had no therapeutic function.
The switch was made over four days, in the pattern of normal restocking cycles. Cassel, reviewing the medications, saw nothing wrong with what he saw — the appearance was identical to what he had been administering, and the divergence would not produce immediate detectable symptoms.
"How long before he shows improvement?" Elias asked, when she briefed him on the intervention.
"Months," she said. "The damage is real and the recovery is slow. But the ongoing damage stops. That's the first thing."
He thought about Prince Edric, whom he had never met, who had been eleven years older than him at the banquet and had spent the intervening decade slowly dying in a wing of the castle he had been born in, under the care of a man who was there to manage his decline. He thought about the prince receiving his medications each day without knowing what they contained, which was not so different from his father receiving a verdict in a proceeding that had been managed without his knowledge.
"The testimony value is real," Lira said. "A recovered prince who can speak to what he experienced — the progression of symptoms, the specific management of his care — is an eyewitness of the highest authority."
"Yes," he said. "But that's a side consideration."
She looked at him.
"The main thing," he said, "is that he stops being poisoned."
She looked at him for a moment. The specific look she gave him when he said something that confirmed something she had been certain of without needing the confirmation.
"Yes," she said. "That's the main thing."
They moved on to the next item on the agenda. The Archive had grown by its most recent and most damning chapter. The prince was, for the first time in nine years, not being actively poisoned. The work continued.